98%
921
2 minutes
20
This study aimed to broaden previous investigations of correlates of lifetime cannabis use and problematic cannabis use among post-secondary students by examining the novel and contemporary issues of medicinal use and deep inhalation practices. The sample included 2212 undergraduate and graduate post-secondary students from Alberta, Canada, who completed the University of Calgary's Campus Experience with Cannabis Survey (average age 23.2, SD = 5.2). Nine variables were entered into the binary logistic regression to examine their differentiation of lifetime users from non-users. A multiple regression model was completed with past six-month users (n = 697), where the continuous dependent variable was cannabis use severity as measured by total scores on the Cannabis Use Disorder Identification Test-Revised. Twenty independent variables were entered simultaneously. Varsity athlete status, family mental illness, severity of alcohol use, greater support for legalization and lower perceived risk associated with regular cannabis use, differentiated lifetime users from non-users. Higher rates of religiosity and living with parents or relatives were associated with lower-lifetime rates. Male gender, earlier age of first cannabis use, cannabis use motives (including coping, enhancement and expansion), past six-month medicinal use and increased frequency of deep inhalation during consumption, were found to be significant correlates of severity. Different factors seem to predict lifetime cannabis use versus severity, and these differences may help inform the development and delivery of prevention efforts. Given that medicinal use and male gender were the largest correlates of severity, populations representing these groups may benefit most from targeted education and prevention.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.addbeh.2019.06.004 | DOI Listing |
Cannabis
July 2025
Institute for Mental Health Policy Research, Centre for Addiction and Mental Health.
Objective: The diversity and potency of cannabis products have increased in recent years, underscoring the importance of understanding which products are being used and why. Patients with substance use disorders (SUDs) use have a high prevalence of risky cannabis use, making it especially important to understand use patterns in this group. We aimed to first describe cannabis product characteristics and then explore reasons for choosing products in our sample.
View Article and Find Full Text PDFJ Gen Intern Med
September 2025
Center for Data to Discovery and Delivery Innovation (3DI), San Francisco VA Health Care System, San Francisco, CA, USA.
Background: Cannabis may cause chronic pulmonary disease. Prior studies have been limited by low cannabis exposure, lack of data on tobacco cigarettes, and/or limited numbers of those without tobacco cigarette use.
Objective: To examine whether inhaled cannabis associated with asthma and chronic obstructive pulmonary disease, independent of tobacco cigarettes.
Subst Use Misuse
September 2025
Department of Psychiatry, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Objective: Adverse experiences during childhood (ACEs) and other adversities, such as experiences of discrimination are important risk factors for substance use, particularly among Black individuals in the United States (U.S.).
View Article and Find Full Text PDFSubst Use Misuse
September 2025
Department of Psychology, Fordham University, New York, New York, USA.
Background: Amidst increasing cannabis legalization in the U.S., greater numbers of older adults are using cannabis; however, few studies have examined how older adults who use cannabis vary with respect to how they use it, where they purchase it, and the consequences they experience.
View Article and Find Full Text PDFViruses
August 2025
Department of Psychiatry, University of California San Diego, San Diego, CA 92093, USA.
Background: Methamphetamine use, which is disproportionately prevalent among people with HIV, increases risk for cardio- and neurovascular pathology through persistent immune activation and inflammation. Preclinical studies indicate that cannabinoids may reduce markers of pro-inflammatory processes, but data from people with chronic inflammatory conditions are limited. We examined potentially interacting associations of lifetime methamphetamine use disorder (MUD), recent cannabis use, and HIV with four plasma markers of immune and inflammatory functions.
View Article and Find Full Text PDF